The Arf tumor suppressor protects against the emergence of oncogene-induced cancers (for reviews, see Kim and Sharpless 2006; Sherr 2006) . With few exceptions, Arf is not expressed during fetal development or in young adult mice. However, elevated levels of sustained proliferative signals conveyed by oncogenes induce Arf expression. In turn, by antagonizing the p53-negative regulator Mdm2, the p19
Arf protein induces a p53 transcriptional response that triggers either cell cycle arrest or apoptosis, thereby eliminating incipient tumor cells. Deletion or epigenetic silencing of Arf abrogates this form of tumor suppression and, not surprisingly, Arf inactivation is frequently observed in many forms of cancer.
Whereas cultured mouse pre-B cells ultimately senesce, their Arf-null counterparts continuously self-renew in culture as long as their proliferation and survival are supported by interleukin-7 (IL-7) (Randle et al. 2001) . Not only are immortalized Arf-null pre-B cells resistant to BCR-ABL-induced apoptosis, but enforced expression of this kinase bypasses their IL-7 requirement (McLaughlin et al. 1987) . Hence, introduction of BCR-ABL into Arf-deficient bone marrow progenitors allows rapid ex vivo outgrowth of pre-B-cell populations that induce a highly aggressive form of acute lymphocytic leukemia (ALL) when inoculated intravenously into healthy, nonconditioned syngeneic mice (Williams et al. 2006) . These leukemias resist therapy with the BCR-ABL kinase inhibitor imatinib (Gleevec), and surprisingly, drug resistance is non-tumor-cell-autonomous. We have now used this system to quantify the effects of Arf inactivation on the generation of BCR-ABL-induced leukemia-initiating cells (LICs), to characterize the clonality of the LIC population, and to explore the basis of their resistance to targeted therapy.
Results and Discussion

BCR-ABL expression and Arf loss are sufficient to generate ALL
A mouse stem cell retroviral vector (MSCV) expressing the human p185 BCR-ABL isoform and encoding GFP from an internal ribosome entry site was packaged into replication-incompetent ecotropic virions. Marrow extracted from the long bones of C57BL/6 mice was infected and cultured on autologous stroma under conditions that selectively yield pre-B cells (Whitlock and Witte 1987) . After 7-8 d of culture, the emerging population uniformly exhibited immunoglobulin (Ig) heavychain gene rearrangements (see below); expressed the Bcell markers B220, CD19, and CD24; and lacked expression of stem cell (Sca-1, Kit) or myeloid (Gr-1, Mac1) surface antigens. Thus, by these criteria, these cultures contained uniform populations of pre-B cells.
Intravenous inoculation of 200,000 p185 + , Arf +/+ donor pre-B cells (or p185-negative Arf −/− cells) into healthy 12-wk-old syngeneic mice failed to induce disease over an 8-mo observation period. However, animals that received only 2000 p185 + , Arf −/− donor cells were moribund by ∼17 d post-injection, and each 10-fold reduction of donor cells down to a limiting dilution of 20 extended the mean latency of disease by ∼3 d (Table 1) . This implied that GFP-marked leukemia cells expanded at a rate that guaranteed a log increase in their number every 3 d (mean generation time of ∼22 h), ultimately leading to replacement of the vast majority of host cells within the bone marrow (Table 1) . When retransplanted into secondary recipients, leukemic cells recovered from such mice induced ALL with similar efficiency (Supplementary Table S1) (Fig. 1A) and contained one to two proviruses integrated at different sites ( 
Arf
−/− pre-B cells generated in short-term cultures have not undergone further selection for emergence of more rapidly proliferating "dominant" clones. Moreover, leukemic cells isolated from moribund animals receiving as few as 200 donor cells were also oligoclonal, whereas mono-or biclonal leukemias arose only in animals receiving 20 cells (Fig. 1C) . Analyses of individual donor cell clones derived by two different methods revealed that the progeny of at least one of every two cells in the polyclonal p185 + , Arf −/− donor population could initiate leukemia (Fig. 2) . Recloning of proviruses from leukemias generated at limiting donor cell dilution and nucleotide sequencing of flanking host cellular sequences confirmed that integrations occurred at distinct chromosomal sites (Supplementary Table S2 ). Although these results do not preclude that insertional mutagenesis or other genetic events might contribute to the relative rate of disease progression, the combination of p185 expression and Arf inactivation is sufficient to generate LICs. Because virtually every donor cell has leukemic capacity, we conclude that these LICs are not rare "cancer stem cells."
Imatinib resistance can be conferred by the hematopoietic microenvironment
Mice inoculated with p185 + , Arf −/− donor cells were treated by oral gavage with a maximum tolerated dose of 100 mg/kg imatinib twice daily. This regimen effectively inhibits the BCR-ABL kinase and induces durable remissions of chronic myelogenous leukemia (CML) in mouse models (Wolff and Ilaria 2001; Hu et al. 2004 Hu et al. , 2006 and, at lower doses, in human patients (Druker et al. 2001 (Druker et al. , 2006 . Pharmacokinetic analysis has indicated that this dosing schedule maintains plasma drug levels >1 µM for >8 h (Wolff et al. 2004) ; this is sufficient to inhibit substrate phosphorylation by BCR-ABL, blocks cyclin D2 synthesis, and prevents the proliferation of leukemic cells in culture (Supplementary Fig. S1A ; Williams et al. 2006) . Although recipient animals were highly resistant to treatment by imatinib (Table 1) , recovered leukemia cells were as sensitive as the donor cells to imatinibinduced proliferative arrest (IC 50 ∼100 nM) (Supplementary Fig. S1A ). Thus, p185 overexpression or kinase mutations affecting drug binding to p185 did not contribute to imatinib resistance, as directly confirmed by nucleotide sequencing of human BCR-ABL genes amplified by PCR and recloned from leukemic cells (Supplementary  Table S3 ).
Although BCR-ABL alleviates the cytokine dependence of primary Arf-null pre-B cells, the IL-7 signaling pathway remains functional; hence, IL-7 addition can attenuate the imatinib response, enabling cells to remain in cycle even when exposed to micromolar drug concentrations (Supplementary Fig. S1A ; Williams et al. 2006) . To determine whether the failure of ALL cells to respond Table S2 ). to imatinib in vivo might be due to cytokine-mediated rescue within the host hematopoietic microenvironment, severe combined immunodeficient (SCID) mice that lack the gene encoding the common ␥-chain (␥ c ) required for signaling by multiple cytokine receptors (IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21) were backcrossed onto the Arf-null C57BL/6 background (Shou et al. 2006) . Bone marrow cells from these mice were briefly transduced in the absence of cytokine support with the p185 vector, and infected cells were infused without intervening culture into lethally irradiated syngeneic recipients. Under these conditions, irradiated mice infused with p185 + wild-type donor cells developed ALL, which was accelerated to a similar degree by Arf or p53 inactivation ( Supplementary Fig. S2 ). Disruption of ␥ c attenuated disease on the Arf-null background, although six of nine injected mice still succumbed to ALL during a 2-mo observation period. The pre-B immunophenotype of these leukemic cells was indistinguishable from that of ALLs arising in their ␥ c + counterparts. Therefore, not only were uncultured p185 + , Arf-null, ␥ c -null donor cells leukemogenic in irradiated hosts, but BCR-ABL kinase activity can completely bypass the requirement for cytokines normally needed for the commitment, differentiation, proliferation, and survival of pre-B cells.
Similarly, when bone marrow cells from Arf-null, ␥ cnull SCID mice were transduced with the vector encoding p185 + and GFP, pre-B cells could be expanded in culture. These ␥ c -null pre-B variants were again indistinguishable from their ␥ c + counterparts with regard to lymphoid morphology, Ig gene rearrangements, and expression of B220, CD19, and CD24. However, as expected, IL-7 addition to p185 + , Arf −/− , ␥ c -null pre-B cells ex vivo no longer attenuated their response to imatinib (Supplementary Fig. S1B ). These p185 + , Arf-null, ␥ c -null donor cells induced ALL in healthy mice (Fig. 3A-C) . Animals receiving 20,000 p185 + donor cells were moribund by ∼21 d post-injection, whereas each 10-fold reduction of donor cells extended the mean latency by ∼5 d (mean generation time, ∼36 h) as compared with 3 d for their ␥ c + counterparts (Fig. 3A-C) . Thus, although BCR-ABL supplants the cytokine requirement for pre-B-cell development in vitro or in vivo, cytokine signaling contributes significantly to the aggressiveness of leukemia.
This begged the question of whether imatinib treatment might prove effective in animals receiving p185
, ␥ c -null donor cells. Because ␥ c -null LICs were less potent than their ␥ c + counterparts, we adjusted the donor cell inocula so that vehicle-treated control mice would all become moribund with a mean latency of <30 d. A proportion of mice still failed therapy (Fig. 3D-F) . Leukemia cells isolated from diseased animals again lacked BCR-ABL mutations. When necropsied, two mice with extensive dissemination of leukemia cells to spleen and blood exhibited brain involvement, consistent with the inability of imatinib to cross the blood-brain barrier (Wolff et al. 2003) . However, gross central nervous system disease was infrequent. In contrast, durable remissions were obtained in a significant number of imatinib- treated mice, yielding long-term survivors (Fig. 3D-F) . As would be expected, the frequency of imatinib-induced remissions was highest in the cohort that received the fewest donor cells (five of six animals). After 70 d of treatment, imatinib therapy was discontinued in animals that had survived. Only one of nine such mice that received only 200 donor cells relapsed over an additional 20-d observation period, whereas eight others have remained healthy 180 d post-therapy. Although multiple signaling pathways might well provide barriers to the eradication of these tumors, we conclude that abrogation of cytokine signaling can significantly improve the therapeutic response to BCR-ABL inhibition. Targeted inhibition of the BCR-ABL kinase by imatinib has revolutionized the therapy of CML (Wong and Witte 2004; Druker et al. 2006) in which the Ph + chromosome is detected in long-term repopulating hematopoietic stem cells (HSCs) (Fialkow et al. 1978; Clarkson et al. 2003; Clarke et al. 2006 ). The disease presents as an indolent myelodysplastic syndrome (the chronic phase) that, when untreated, leads to aggressive myeloid or lymphoid blast crisis. CML conforms to the emerging "cancer stem cell" model (Clarke et al. 2006) in that it arises from a small reservoir of tumorigenic, HSC-like Ph + progenitor cells that self-renew but also differentiate into heterogeneous blood cell types that, although comprising the bulk of the leukemia, are themselves nontumorigenic and relatively short-lived. In the chronic phase of CML, deletions of CDKN2A (INK4A/ARF) have not been observed, presumably because the locus is normally silenced in stem cells (Jacobs et al. 1999; Park et al. 2003) , thereby abrogating its oncogene-induced activation and subsequent selection for loss of function. In this setting, mutations of BCR-ABL account for most drug resistance (Shah et al. 2002) , and second-generation inhibitors like dasatinib (Sprycel) and nilotinib that inhibit many mutant forms of the kinase can effectively induce second remissions Talpaz et al. 2006; Hochhaus et al. 2007) .
In contrast, imatinib has proven less successful in treating Ph + ALL (Druker et al. 2001; Talpaz et al. 2006; Alvarado et al. 2007; de Labarthe et al. 2007) . Although clinical trials of both imatinib and dasatinib in Ph + ALL have clearly demonstrated the efficacy of both drugs, remissions are of relatively shorter duration due to more rapid outgrowth of resistant subclones bearing BCR-ABL kinase mutations (Talpaz et al. 2006; Hochhaus et al. 2007; O'Hare et al. 2007) . In Ph + ALL arising de novo (and distinguished from lymphoid blast crisis in CML), the LICs appear to be committed lymphoid progenitors (Castor et al. 2005) in which the INK4A/ARF checkpoint can be activated. In turn, deletion of the INK4A/ARF locus occurs in Ph + ALL cases (Heerema et al. 2004; Primo et al. 2005; Mullighan et al. 2007) ; indeed, a recent survey of 21 pediatric and 22 adult cases has documented INK4A-ARF deletion in Ph + ALL blasts taken from ∼50% of patients at diagnosis (Mullighan et al. 2007 ) (J. Downing, C. Mullighan, R.T. Williams, and C.J. Sherr, unpubl.) . In our mouse model, the use of Arf-null donor cells negates the requirement for p185-induced deletion and instead leads rapidly to fatal drug-resistant disease, thereby leaving little time to accrue leukemic subpopulations that acquire mutations in BCR-ABL itself. We speculate that in human Ph + ALL, INK4A-ARF deletion might help maintain LIC survival in the face of targeted drug therapy and facilitate the emergence of drug resistant BCR-ABL variants. As such, INK4A-ARF deletion might prove to be a poor prognostic indicator.
Materials and methods
Gene transduction, cell culture, and transplantation Arf-null mice backcrossed onto a C57Bl/6 background from our own colony (Kamijo et al. 1997) were intercrossed with syngeneic ␥ c -null mice to generate Arf-null SCID animals (Shou et al. 2006) . MSCV vectors coexpressing human p185 and GFP were provided by Owen Witte (University of California at Los Angeles, Los Angeles, CA) and were packaged into replication-incompetent ecotropic virions as described (Zindy et al. 1998) . Marrow extracted from the long bones of mice was suspended in vector-containing supernatant and plated to derive pre-B cells on autologous stroma (Whitlock and Witte 1987; Williams et al. 2006) . After 7-8 d of culture, defined numbers of pre-B cells were infused intravenously into cohorts of healthy 12-wk-old C57Bl/6 mice. For some experiments, single cells were sorted into 96-well culture dishes by flow cytometry, and cultures were expanded in the same medium. For transplantation of irradiated recipients, donor bone marrow cells were transduced for 3 h in the absence of cytokine support with a vector encoding p185, and infected cells (1 × 10 6 per recipient mouse) were infused without intervening culture into lethally irradiated (11 Gy in two fractions) animals. To quantify cytostatic effects of imatinib, cells plated at 2 × 10 4 per well in 96-well plates were cultured in the presence or absence of 10 ng/mL recombinant IL-7 (R&D Systems), and imatinib (Novartis) was added to achieve the indicated concentrations. Cell growth was quantified 72 h later by a methane-thiosulfonate-base assay (CellTiter 96 Aqueous One Solution reagent, Promega).
Southern blotting and molecular cloning of proviral integrations
Genomic DNA extracted from single-cell-derived pre-B clones or from leukemic bone marrow obtained from moribund mice was digested with XbaI or EcoRI to detect Ig heavy-chain gene rearrangements or proviral integrations, respectively. DNA digests (20 µg per lane) were separated on 0.7% agarose gels and transferred to Nytran SuPerCharge (SPC) nylon membranes (Whatman, Inc.). Membranes were prehybridized at 68°C for at least 1 h with PerfectHyb Plus (Sigma-Aldrich, Inc.) containing 100 µg/mL salmon sperm DNA. Radiolabeled probes prepared with [␣-32 P] dATP by random priming (Roche Diagnostics) were then added, and hybridization was continued for 16 h. Ig heavy-chain gene rearrangements were visualized using a radiolableled 1.2-kb BamHI-XbaI J H fragment cloned from Balb/c mouse liver (Borzillo and Sherr 1989) ; a 1.4-kb EcoRIClaI IRES-GFP fragment isolated from the MSCV-IRES-GFP retroviral vector was used to detect proviral integrations. Membranes were briefly rinsed in 2× SSC (1× SSC is 0.15 M NaCl/0.015 M Na citrate) containing 0.1% SDS at room temperature followed by a stringent wash in 0.1× SSC/0.1% SDS for 30 min at 60°C. Dried membranes were exposed to Kodak BioMax MR film (Kodak) at −80°C. Proviral integrations were cloned using an inverse PCR technique (Dominici et al. 2004) . A detailed description of PCR conditions and primers appears in the legend for Supplementary Table S2 .
Monitoring of disease and imatinib treatment
Cohorts of male mice injected intravenously with donor cells were observed daily and sacrificed when moribund (dehydration, ruffled fur, poor mobility, respiratory distress). Treatment was initiated 3 d after cell injection by twice-daily oral gavage with vehicle alone or with imatinib (100 mg/kg) and continued until animals became sick or until the indicated times if mice remained healthy. throughout the course of this work. These studies were supported in part by Cancer Center Core Grant CA-21765 and ALSAC of St. Jude Children's Research Hospital. C.J.S. is an Investigator of the Howard Hughes Medical Institute.
